Prevalence of primary immune thrombocytopenia in Oklahoma

被引:69
|
作者
Terrell, Deirdra R. [1 ]
Beebe, Laura A. [1 ]
Neas, Barbara R. [1 ]
Vesely, Sara K. [1 ]
Segal, Jodi B. [2 ]
George, James N. [1 ,3 ]
机构
[1] Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Dept Biostat & Epidemiol, Oklahoma City, OK 73126 USA
[2] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
[3] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Med, Oklahoma City, OK 73126 USA
关键词
QUALITY-OF-LIFE; PURPURA; ADULTS; CHILDHOOD; CHILDREN; PATIENT;
D O I
10.1002/ajh.23262
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To determine the prevalence of immune thrombocytopenia (ITP) in Oklahoma regardless of age, clinical characteristics, insurance status, and source of health care. Patients with ITP were identified by the administrative code ICD-9-CM 287.3 in Oklahoma hematologists' offices for a 2-year period, 20032004. Prevalence was estimated separately for children (<16 years old) and adults because of their distinct clinical characteristics. Oklahoma census data for 2000 was used as the denominator. Eighty-seven (94%) of 93 eligible Oklahoma hematologists participated; 620 patients with ITP were identified. The average annual prevalences were as follows: 8.1 (95% CI: 6.79.5) per 100,000 children, 12.1 (95% CI: 11.113.0) per 100,000 adults, and 11.2 (95% CI: 10.412.0) per 100,000 population. Among children and adults less than age 70 years, the prevalence was greater among women. Among adults aged 70 years and older, the prevalence was greater among men. The highest prevalence of ITP was among men age 80 years and older. These data document for the first time the prevalence of ITP regardless of age, clinical characteristics, insurance status, and source of health care. The methodology developed for this prevalence analysis may be adaptable for epidemiologic studies of other uncommon disorders which lack specific diagnostic criteria and are treated primarily by medical specialists. Am. J. Hematol. 2012. (c) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:848 / 852
页数:5
相关论文
共 50 条
  • [41] Avatrombopag for the Treatment of Immune Thrombocytopenia
    Labanca, Caterina
    Vigna, Ernesto
    Martino, Enrica Antonia
    Bruzzese, Antonella
    Mendicino, Francesco
    Carida, Giulio
    Lucia, Eugenio
    Olivito, Virginia
    Puccio, Noemi
    Neri, Antonino
    Morabito, Fortunato
    Gentile, Massimo
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2025,
  • [42] Fibrinogen levels are associated with bleeding in patients with primary immune thrombocytopenia
    Xu, Min
    Luo, Lin
    Du, Mengyi
    Tang, Lu
    Hu, Yu
    Mei, Heng
    PLATELETS, 2020, 31 (06) : 763 - 770
  • [43] Incidence of adult primary immune thrombocytopenia in England-An update
    Doobaree, Indraraj Umesh
    Conway, Katherine
    Miah, Haroon
    Miah, Atiqa
    Makris, Michael
    Hill, Quentin
    Cooper, Nicola
    Bradbury, Charlotte
    Newland, Adrian
    Provan, Drew
    McDonald, Vickie
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (03) : 238 - 249
  • [44] Adolescents and young adults with newly diagnosed primary immune thrombocytopenia
    Schifferli, Alexandra
    Moulis, Guillaume
    Godeau, Bertrand
    Leblanc, Thierry
    Aladjidi, Nathalie
    Michel, Marc
    Leverger, Guy
    Elalfy, Mohsen
    Grainger, John
    Chitlur, Meera
    Heiri, Andrea
    Holzhauer, Susanne
    le Gavrian, Gautier
    Imbach, Paul
    Kuhne, Thomas
    HAEMATOLOGICA, 2023, 108 (10) : 2783 - 2793
  • [45] Time trends in incidence and prevalence of immune thrombocytopenia: A nationwide cohort analysis
    Lawrie, Dana Audrey
    Mannering, Nikolaj
    Hansen, Dennis Lund
    Frederiksen, Henrik
    BRITISH JOURNAL OF HAEMATOLOGY, 2023,
  • [46] Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia
    Newland, Adrian C.
    Sanchez-Gonzalez, Blanca
    Rejto, Laszlo
    Egyed, Miklos
    Romanyuk, Nataliya
    Godar, Marie
    Verschueren, Katrien
    Gandini, Domenica
    Ulrichts, Peter
    Beauchamp, Jon
    Dreier, Torsten
    Ward, E. Sally
    Michel, Marc
    Liebman, Howard A.
    de Haard, Hans
    Leupin, Nicolas
    Kuter, David J.
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (02) : 178 - 187
  • [47] Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain
    Ramon Gonzalez-Porras, Jose
    Parrondo Garcia, Francisco Javier
    Anguita, Eduardo
    FARMACIA HOSPITALARIA, 2020, 44 (06) : 279 - 287
  • [48] lncRNA GAS5 and RUNX1 Genes in Children With Primary Immune Thrombocytopenia
    Hodeib, Hossam
    El Amrousy, Doaa
    Elaskary, Eman
    Hablas, Nahed
    Youssef, Amira
    Abdelhai, Dina
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2023, 45 (03) : E395 - E400
  • [49] Burden of immune thrombocytopenia (ITP): Special considerations for refractory ITP
    Rufer, Axel
    Terrell, Deirdra R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 203 (01) : 79 - 85
  • [50] Immune thrombocytopenia
    Matzdorff, A.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2011, 136 (22) : 1172 - 1174